

AstraZeneca AB
SE-151 85 Södertälje
Sweden

AstraZeneca



For more information,
scan here or visit
www.azcovid-19.com

EU/1/21/1529/001

Store in a refrigerator.
Keep vials in outer carton in order to protect from light.
Do not freeze. Do not shake.
Read the package leaflet before use. For information on the shelf life after first opening and additional storage information, see the package leaflet. This medicine contains genetically modified organisms (GMOs).
Dispose of in compliance with the local guidance for pharmaceutical waste.
Keep out of the sight and reach of children.
One dose (0.5 ml) contains not less than 2.5×10^8 infectious units
Excipients: L-histidine, L-histidine hydrochloride monohydrate, magnesium chloride hexahydrate, polysorbate 80 (E 433), ethanol, sucrose, sodium chloride, disodium edetate (dihydrate), water for injections.

Lot
EXP
PC
SN
AB###
MM-YY
Vaxzevria Qata 3
Variable data 4



Vaxzevria™
suspension for injection

COVID-19 Vaccine
(ChAdOx1-S [recombinant])

10 multidose vials
(8 doses per vial - 0.5 ml per dose)

4 ml

123456



Vaxzevria™
suspension for injection

COVID-19 Vaccine
(ChAdOx1-S [recombinant])

Intramuscular use

10 multidose vials
(8 doses per vial - 0.5 ml per dose)

4 ml

AstraZeneca

106 x 81 x 41 mm

Vaxzevria™
suspension for injection
COVID-19 Vaccine (ChAdOx1-S
[recombinant])

4 ml

10 multidose vials
(8 doses per vial - 0.5 ml per dose)

Tamper Evident Label